Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: A cost-effectiveness analysis

BJU International

Volumn 111, Issue 7, 2013, Pages 1054-1060

  Hilton, William M ^a   Lotan, Yair ^b   Parekh, Dipen J ^a   Basler, Joseph W ^a   Svatek, Robert S ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alvimopan; cost effectiveness; cystectomy; ileus; Markov model

Indexed keywords

ALVIMOPAN;

ABDOMINAL SURGERY; ARTICLE; BLADDER CANCER; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYSTECTOMY; DECISION TREE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; INTESTINE FUNCTION; LENGTH OF STAY; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PARALYTIC ILEUS; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PARALYTIC ILEUS; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; CYSTECTOMY; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL PSEUDO-OBSTRUCTION; LENGTH OF STAY; MALE; PIPERIDINES; POSTOPERATIVE PERIOD;

EID: 84877697713     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11499.x     Document Type: Article

References (27)

1. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55: 164-174
2. Svatek RS, Fisher MB, Matin SF, et al. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol 2010; 183: 929-934
3. Resnick J, Greenwald DA, Brandt LJ,. Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part I. Am J Gastroenterol 1997; 92: 751-762
4. Resnick J, Greenwald DA, Brandt LJ,. Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part II. Am J Gastroenterol 1997; 92: 934-940
5. Schuster TG, Montie JE,. Postoperative ileus after abdominal surgery. Urology 2002; 59: 465-471
6. Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA Jr,. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 2003; 169: 101-104
7. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009; 55: 177-185
8. Hollenbeck BK, Miller DC, Taub D, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol 2005; 174: 1231-1237
9. Svatek RS, Fisher MB, Williams MB, et al. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology 2010; 76: 1419-1424
10. Asgeirsson T, El-Badawi KI, Mahmood A, Barletta J, Luchtefeld M, Senagore AJ,. Postoperative ileus: it costs more than you expect. J Am Coll Surg 2010; 210: 228-231
11. Foss JF, Fisher DM, Schmith VD,. Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials. Clin Pharmacol Ther 2008; 83: 770-776
12. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004; 240: 728-735
13. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005; 48: 1114-1125; discussion 1125-6; author reply 1127-9
14. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006; 20: 64-70
15. Techner L,. A phase 4, multicenter, double-blind, placebo-controlled, parallel study of alvimopan for the management of postoperative ileus in subjects undergoing radical cystectomy. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US), 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT00708201. Accessed August 2012
16. Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith JA Jr,. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 2002; 167: 2012-2016
17. Lee KL, Freiha F, Presti JC Jr, Gill HS,. Gender differences in radical cystectomy: complications and blood loss. Urology 2004; 63: 1095-1099
18. Soulie M, Straub M, Game X, et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol 2002; 167: 1325-1328
19. National Aeronautics and Space Administration (NASA). Gross Domestic Product Deflator Inflation Calculator. 2007 [Cited 12 March 2012]. Available at: http://cost.jsc.nasa.gov/inflategdp.html. Accessed August 2012
20. Coombe R, Schaefer M,. National PBM Drug Monograph Alvimopan Monograph. Kansas City: VHA Pharmacy Benefits Management Services and the Medical Advisory Panel, 2009
21. Iyer S, Saunders WB, Stemkowski S,. Economic burden of postoperative ileus associated with colectomy in the United States. J Manag Care Pharm 2009; 15: 485-494
22. Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg 2008; 143: 1098-1105
23. Buchles MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management of posto-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther 2008; 89: 312-325
24. Wolff BG, Weese JL, Ludwig KA, et al. Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg 2007; 204: 609-616
25. Bell TJ, Poston SA, Kraft MD, Senagore AJ, Delaney CP, Techner L,. Economic analysis of alvimopan in North American Phase III efficacy trials. Am J Health Syst Pharm 2009; 66: 1362-1368
26. Food and Drug Administration Web site. Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) To Evaluate Entereg (Alvimopan) for the Acceleration of Recovery Time to Upper and Lower Gastrointestinal Recovery Following Partial Large or Small Bowel Resection Surgery with Primary Anastomosis. 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4336b1-01-fda.pdf. Accessed 20 April 2012
27. Lee CT, Dunn RL, Chen BT, Joshi DP, Sheffield J, Montie JE,. Impact of body mass index on radical cystectomy. J Urol 2004; 172: 1281-1285